Effects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE)

NCT07579390 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3500

Last updated 2026-05-14

No results posted yet for this study

Summary

The STEPCARE-MAKE study is a predefined sub-study of the large Sedation, TEmperature and Pressure after Cardiac Arrest and REsuscitation (STEPCARE) trial, which evaluates the effects of three interventions in comatose adult patients resuscitated from out-of-hospital cardiac arrest. In this sub-study, all 3500 participants enrolled in the main trial are assessed for major adverse kidney events (MAKE) and creatinine kinetics.

Conditions

  • Acute Kidney Failure
  • Renal Replacement Therapy for Acute Kidney Injury in ICU
  • Sedation in Intensive Care Unit Patients
  • Sedation in the ICU
  • Sedation in Intensive Care
  • Blood Pressure
  • Mean Arterial Pressure Targets
  • Temperature
  • Fever
  • Resuscitated Sudden Cardiac Death
  • Out of Hospital Cardiac Arrest
  • Cardiac Arrest (CA)

Interventions

DEVICE

Feedback-controlled temperature device

If core body temperature exceeds 37.7°C a feedback-controlled device will be used and set at 37.5°C

OTHER

High MAP

A MAP target of \>85mmHg will be used. Vasopressors will be titrated to this target during 36h

OTHER

Deep sedation

Deep sedation for at least 36h

OTHER

Fever control without a device

Management of fever in the ICU without a device

OTHER

Low MAP

A MAP target of \>65mmHg will be used. Vasopressors will be titrated to this target during 36h

OTHER

Minimal sedation

A strategy of minimal sedation in the ICU, sedation used only as needed to facilitate transport, imaging and invasive procedures

Sponsors & Collaborators

  • Helsinki University Central Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-17
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Australia
  • Belgium
  • Estonia
  • Finland
  • Germany
  • Italy
  • Luxembourg
  • New Zealand
  • Norway
  • Saudi Arabia
  • Singapore
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07579390 on ClinicalTrials.gov